MICROPOS MEDICAL ABMM

MICROPOS MEDICAL AB

1.945SEKD
+0.105+5.71%
As of today at 07:12 GMT
SEK
No trades
See on Supercharts

MPOS fundamentals

Key facts

Market capitalization‪332.72 M‬SEK
Basic EPS (TTM)−0.14SEK
Founded2003
CEOThomas Lindström
About

Micropos Medical AB engages in the development and sale of medical devices. The firm develops technologies for radiotherapy of cancer. It offers RayPilot, a tumor tracking electromagnetic positioning system for prostate cancer and other tumor areas. The company was founded by Bengt Rosengren, Bo Nils Lennernäs, Sten Nilsson and Seymour Levitt in 2003 and is headquartered in Gothenburg, Sweden.

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪332.72 M‬‬
Price to earning ratio (P/E)
Price to sales ratio (P/S)
87.36x
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
Price to sales ratio (P/S)
87.36x
Valuation ratios
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪0.00‬
‪40.00‬
‪80.00‬
‪120.00‬
‪160.00‬
P/S

Growth and Profitability

Company’s recent performance and margins

Performance
‪−8,250.00%‬
‪−6,250.00%‬
‪−4,250.00%‬
‪−2,250.00%‬
‪−250.00%‬
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪‪−7.50 M‬‬
‪‪−5.00 M‬‬
‪‪−2.50 M‬‬
‪0.00‬
‪‪2.50 M‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪‪−6.00 M‬‬
‪‪−4.00 M‬‬
‪‪−2.00 M‬‬
‪0.00‬
‪‪2.00 M‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪‪−6.00 M‬‬
‪‪−4.00 M‬‬
‪‪−2.00 M‬‬
‪0.00‬
‪‪2.00 M‬‬

Revenue breakdown

Revenue streams and regions a business earns money from

By source/business
Period: 2024
Raypilot Systems and Equipment
By country
Period: 2024
Sweden

Dividends

Dividend yield, history and sustainability

MPOS does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future

Financial health

Financial position and solvency of the company

Debt level and coverage
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪‪−8.00 M‬‬
‪0.00‬
‪‪8.00 M‬‬
‪‪16.00 M‬‬
‪‪24.00 M‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
Short term
Long term
‪0.00‬
‪‪4.00 M‬‬
‪‪8.00 M‬‬
‪‪12.00 M‬‬
‪‪16.00 M‬‬
Assets
Liabilities